AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Merck MRK continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

New Jersey’s pharma sector faces new layoffs as Merck cuts 204 jobs and Bristol Myers Squibb plans 110 reductions amid ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its ...

A Manhattan federal jury found Merck & Co. discriminated against a director of compliance and risk management by terminating ...